Corvus Pharmaceuticals Q4 net loss widens on higher R&D costs

Overview

• U.S. biopharma firm's Q4 net loss widened as operating expenses rose on clinical trial costs

• Company reported positive Phase 1 safety and efficacy data for soquelitinib in atopic dermatitis

• Corvus completed raising $189 mln in public offering, extending cash runway into Q2 2028

Outlook

• Corvus expects cash to fund operations into the second qtr of 2028

Result Drivers

• CLINICAL TRIAL COSTS - Higher research and development expenses were mainly due to increased clinical trial and manufacturing costs for soquelitinib, along with higher personnel costs

• Research and development expenses for the three months and year ended December 31, 2025 totaled $9.9 million and $33.7 million, respectively, compared to $6.0 million and $19.4 million for the same periods in 2024.

• Corvus had cash, cash equivalents and marketable securities of $56.8 million as compared to $52.0 million as of December 31, 2024

Company press release: ID:nGNX3P6Plt

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $31.00, about 83.4% above its March 11 closing price of $16.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.